Retinoic acid and arsenic for treating acute promyelocytic leukemia.

Guang-Biao Zhou,Wei-Li Zhao,Zhen-Yi Wang,Sai-Juan Chen,Zhu Chen

DOI: https://doi.org/10.1371/journal.pmed.0020012

2005-01-01

PLoS Medicine

Abstract:What were the critical steps in the development of ATRA and arsenic as treatments for APL? Researchers in Shanghai tell the story and look to the future.

What problem does this paper attempt to address?

Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia

Yinjun Lou,Yafang Ma,Jie Jin,Honghu Zhu

DOI: https://doi.org/10.3389/fonc.2020.597601

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with two oral agents. Indeed, the oral RIF plus all-trans-retinoic acid (ATRA) without chemotherapy display highly efficacy in patients with APL. The safety profile of RIF plus ATRA make possible to treat APL patients in a home-based manner during postremission therapy. To our knowledge, RIF was the first commercially available oral arsenic agent approved in China. The RIF plus ATRA regimens are becoming a preferred frontline care for APL in China. In this review, we will discuss the history, current evidences and challengers of RIF-based strategies in APL. More and more APL patients may enjoy a cure with a normal quality-of-life after induction in the near future.
Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Yinjun Lou,Wenbin Qian,Haitao Meng,Wenyuan Mai,Hongyan Tong,Yin Tong,Jian Huang,Jie Jin

DOI: https://doi.org/10.1002/hon.2076

IF: 4.85

2014-01-01

Hematological Oncology

Abstract:We evaluated the efficacy of low-dose all-trans retinoic acid (ATRA) plus minimal chemotherapy for induction in newly diagnosed acute promyelocytic leukaemia (APL). Furthermore, we compared its long-term outcome with or without the addition of intravenous arsenic trioxide (ATO) in post-remission therapy. From January 2004 to September 2011, a total of 109 patients with a median age of 41years (range 14-73) were enrolled in the study. Two arms were assigned according to post-remission protocols: ATO group cases were subsequently treated with intravenous ATO, standard chemotherapy, and ATRA. No-ATO group cases were subsequently treated with chemotherapy and ATRA only. Patients were monitored of minimal residual disease (MRD) by reverse-transcriptase polymerase chain reaction. The haematologic complete remission (CR) rate was 96.3%. The early death rate was 0.9%. At a median follow-up of 49months (range 8-102months), the Kaplan-Meier estimates of 5-year relapse-free survival were significantly better for patients in the ATO group than in the no-ATO group, 94.4% vs 54.8% (p=0.0001), and the 5-year overall survival rate was 95.7% vs 64.1%, in the two groups (p=0.003). Our data show that low-dose ATRA plus minimal chemotherapy exhibits efficacy in induction therapy for untreated APL and suggest that the addition of ATO to post-remission therapy significantly improves the long-term outcome. Copyright (c) 2013 John Wiley & Sons, Ltd.
The Simpler, The Better: Oral Arsenic For Acute Promyelocytic Leukemia

Hong-Hu Zhu,Jiong Hu,Francesco Lo-Coco,Jie Jin

DOI: https://doi.org/10.1182/blood.2019000760

IF: 20.3

2019-01-01

Blood

Abstract:Arsenic trioxide and all-trans retinoic acid have become the frontline treatments for patients with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a commercially available agent, realgar-indigo naturalis formula (RIF), was not launched in China until 2009. Since then, over 5000 APL patients have been treated with oral RIF in China. Oral arsenic not only shows a clinical efficacy comparable to that of IV formulations but also displays a better safety profile, improved quality of life, and lower medical costs for patients. The promising results promote incorporating an outpatient postremission therapy model into clinical practice for both low-risk and high-risk APL patients in China. In this review, we discuss the evolution of oral arsenic RIF in the treatment of APL, with a special focus on how to address the related complications during induction therapy.
Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

Yinjun Lou,Jie Jin

DOI: https://doi.org/10.1182/blood.v120.21.1480.1480

IF: 20.3

2012-01-01

Blood

Abstract:Abstract 1480 Acute promyelocytic leukemia (APL) is a distinct subtype of acute myelogenous leukemia (AML), which usually presents with pancytopenia, coagulopathies and bleeding. Molecular studies have revealed that it was caused by leukemogenic PML-RARA fusion gene resulting from a specific chromosomal translocation t(15;17). The administration of target agent all-trans-retinoic acid (ATRA) combined with anthracycline-based chemotherapy for induction and consolidation followed by ATRA plus low-dose chemotherapy maintenance is the standard strategies for patients with newly diagnosed APL. However, despite the high cure rate, early death and leukemia relapse are the two main important obstacles. We evaluated the efficacy of low-dose All-trans-retinoic acid (ATRA) plus individually adapted chemotherapy for induction followed by arsenic trioxide (ATO) based post-remission therapy in newly diagnosed acute promyelocytic leukemia (APL). From January 2004 to September 2011, 109 patients with APL were enrolled the study. The complete remission (CR) rate was 96.3%. The early death rate was 0.9%. Two arms were assigned according to post-remission protocols: ATO group cases were treated with standard chemotherapy, ATO, and ATRA. Without ATO group cases were subsequently treated with chemotherapy and ATRA only. Patients were monitored by reverse transcriptase-polymerase chain reaction (RT-PCR) during and after treatment. The six-year relapse-free survival (RFS) was significantly better for patients in ATO group than in without ATO group, 94.4% versus 50.6% (P < 0.0001) and the six-year overall survival (OS) rate was 95.7% versus 64.1%, in two groups (P = 0.003). This study shows that low-dose ATRA plus tailored chemotherapy is effective in induction therapy, and the addition of ATO to post-remission therapy significantly improves the long-term outcome. Disclosures: No relevant conflicts of interest to declare.
The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Ying Lu,Fenglin Li,Qitian Mu,Haitao Meng,Wenbin Qian,Hongyan Tong,Wenyuan Mai,Renzhi Pei,Mengxia Yu,Xiaoying Zhao,Jie Jin

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2015.05.004

2015-01-01

Abstract:OBJECTIVE:To investigate the clinical efficacy of all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) in induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL). METHODS:A retrospective analysis of 298 newly diagnosed APL patients from the department of hematology, First Affiliated Hospital of Zhejiang University since September 2004 to December 2013, including 177 cases with ATRA plus ATO and 116 ATRA plus chemotherapy (CT), was performed to investigate the clinical efficacy between the low-intermediate (WBC≤10×10⁹/L) and high (WBC>10×10⁹/L) risk APL patients, respectively. RESULTS:For the low-intermediate risk patients, the relapse rate in ATRA plus CT and ATRA plus ATO are 22.0% and 6.1% (P=0.004), respectively; the 3 years estimated relapse-free survival (RFS) are 78.0% and 92.9% (P=0.021), respectively. For the high risk patients, the relapse rate in ATRA plus CT and ATRA plus ATO are 25.0% and 5.2% (P=0.035), respectively; the 3 years estimated RFS rate were 80.8% and 93.0% (P=0.021), respectively. But the rate of early death (ED), complete remission (CR) and overall survival (OS) between the two therapy protocols had no statistical difference (P>0.05). CONCLUSION:ATRA plus ATO in induction and maintenance therapy might prolong the RFS time of the low-intermediate risk APL patients and decrease the relapse rate of the low, intermediate and high risk APL patients.
Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.

Yinjun Lou,Ying Lu,Zhijuan Zhu,Yafang Ma,Shanshan Suo,Yungui Wang,Dong Chen,Hongyan Tong,Wenbin Qian,Haitao Meng,Wenyuan Mai,Wenjun Yu,Weilai Xu,Lei Wang,Liping Mao,Renzhi Pei,Jie Jin

DOI: https://doi.org/10.1002/hon.2519

IF: 4.85

2018-01-01

Hematological Oncology

Abstract:Limited data was available for long-term follow-up in newly diagnosed acute promyelocytic leukemia (APL) patients treated with all-trans-retinoic acid (ATRA) plus intravenously arsenic trioxide (ATO)-based front-line therapy. The aim of this work was to retrospectively analyze the long-term survival rate and frequency of therapy-related myeloid neoplasia (t-MN) occurring in a large cohort of APL patients. A total of 760 newly diagnosed patients with APL between January 1999 and May 2016 were evaluated. The early death rate was 9.2% (70/760). Of the remaining 690 patients with complete remission, patients were grouped according to front-line regimens: ATRA plus ATO with or without chemotherapy (ATO group) and ATRA with chemotherapy (non-ATO group). The median duration of follow-up was 7.5 years (1.0-18.3 years). ATO group showed significant superior 10-year estimated relapse-free survival (RFS) up to 90.3% comparing with 65.5% in the non-ATO group (P < 0.0001). In addition, the 10-year estimated overall survival (OS) was 93.9% for patients in the ATO group and 89.1% for those in the non-ATO group (P = 0.03). In the subgroup analysis, the RFS rate was also higher in ATO group comparing with non-ATO group in both low-to-intermediate-risk (94.2% vs 64.6%, P < 0.0001) and high-risk subgroup (89.6% vs 74.7%, P = 0.04). Notably, the 3-year RFS and OS rates in the chemotherapy-free subgroup of the low-to-intermediate-risk patients (n = 88) were 100% and 100%, respectively. In the entire cohort, a total of 10 patients developed secondary malignant neoplasms, including 7 patients with therapy-related myeloid neoplasms (t-MN). The estimated 5-year cumulative incidence risk of t-MN in the ATO and non-ATO groups was 1.0% and 0.4%, respectively (P = 0.34). Thus, our data revealed that the long-term outcome of patients treated with ATRA plus ATO-based regimens was associated with continuing high efficacy in all Sanz risk patients with newly diagnosed APL.
Oral Arsenic And All-Trans Retinoic Acid For High-Risk Acute Promyelocytic Leukemia

Hong-Hu Zhu,Yan-Rong Liu

DOI: https://doi.org/10.1182/blood-2018-02-834051

IF: 20.3

2018-01-01

Blood

Abstract:TO THE EDITOR:Acute promyelocytic leukemia (APL) has now become a highly curable disease using an all- trans retinoic acid (ATRA) and arsenic trioxide (ATO)–based treatment. The practice-changing study APL0406 reported by Lo-Coco et al demonstrated that non–high-risk APL patients, defined by a
Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

Z Chen,GQ Chen,ZX Shen,SJ Chen,ZY Wang

DOI: https://doi.org/10.1053/shem.2001.20863

IF: 3.754

2001-01-01

Seminars in Hematology

Abstract:Arsenic compounds, including arsenic trioxide (As2O3) and arsenic sulfide (As4S4), have recently been shown to be effective in the treatment of acute promyelocytic leukemia (APL). In vitro, As2O3 exerts a dosedependent dual effect: it triggers apoptosis at relatively high concentrations (0.5 to 2.0 μmol/L) and induces partial differentiation at low concentrations (0.1 to 0.5 μmmol/L). The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the retinoic acid signaling is required for APL cell differentiation. As2O3 over a wide range of concentrations (0.1 to 2.0 μmol/L) induces degradation of PML-RARα as well as the wild-type PML and enhances the acetylation of histone, a process important for the transcriptional activation of genes. In vivo, As2O3 induces a high complete remission (CR) rate in patients with both primary and relapsed APL (around 85% to 90%). Side effects, such as skin reaction, gastrointestinal symptoms, electrocardiographic (EKG) changes, neuropathy, and liver dysfunction, are mild to moderate in relapsed patients, and severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as postremission therapy has yielded better survival than treatment with As2O3 alone. This is in line with the observation that remission induction with As2O3 is not sufficient in most cases to obtain a molecular remission as judged by reverse-transcriptase polymerase chain reaction for PML-RARα fusion transcripts. The in vivo effect of As2O3 seems to be related to the expression of APL-specific PML-RARα oncoprotein, and a synergistic effect between As2O3 and ATRA has been shown in the APL mouse model. Besides As2O3, other arsenic compounds such as As4S4 also show a therapeutic effect in APL. Because the toxic effects of arsenic treatment in primary APL need to be investigated further, we propose use of ATRA as a first-line drug for remission induction in primary APL, whereas As2O3 can be incorporated into multidrug postremission therapy or used as rescue for relapsed APL patients.
Long-Term Efficacy and Safety of All-Trans Retinoic Acid/Arsenic Trioxide-Based Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

Jiong Hu,Yuan-Fang Liu,Chuan-Feng Wu,Fang Xu,Zhi-Xiang Shen,Yong-Mei Zhu,Jun-Min Li,Wei Tang,Wei-Li Zhao,Wen Wu,Hui-Ping Sun,Qiu-Sheng Chen,Bing Chen,Guang-Biao Zhou,Arthur Zelent,Samuel Waxman,Zhen-Yi Wang,Sai-Juan Chen,Zhu Chen

DOI: https://doi.org/10.1073/pnas.0813280106

2009-01-01

Abstract:All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) combination-based therapy has benefitted newly diagnosed acute promyelocytic leukemia (APL) in short-term studies, but the long-term efficacy and safety remained unclear. From April 2001, we have followed 85 patients administrated ATRA/ATO with a median follow-up of 70 months. Eighty patients (94.1%) entered complete remission (CR). Kaplan-Meier estimates of the 5-year event-free survival (EFS) and overall survival (OS) for all patients were 89.2% +/- 3.4% and 91.7% +/- 3.0%, respectively, and the 5-year relapse-free survival (RFS) and OS for patients who achieved CR (n = 80) were 94.8% +/- 2.5% and 97.4% +/- 1.8%, respectively. Upon ATRA/ATO, prognosis was not influenced by initial white blood cell count, distinct PML-RAR alpha types, or FLT3 mutations. The toxicity profile was mild and reversible. No secondary carcinoma was observed, and 24 months after the last dose of ATRA/ATO, patients had urine arsenic concentrations well below the safety limit. These results demonstrate the high efficacy and minimal toxicity of ATRA/ATO treatment for newly diagnosed APL in long-term follow-up, suggesting a potential frontline therapy for de novo APL.
The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia.

Hong‐Hu Zhu,Jiong Hu,Francesco Lo‐Coco,Jie Jin

DOI: https://doi.org/10.1182/blood.2019000760

IF: 20.3

2019-01-01

Blood

Abstract:Arsenic trioxide (ATO) and all-trans retinoic acid have become the front-line treatments for patients with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a commercially available agent, "Realgar-Indigo naturalis formula (RIF)", was not launched in China until 2009. Since then, over 5000 patients with APL have been treated with oral RIF in China. Oral arsenic not only shows a clinical efficacy comparable to that of IV formulations but also displays a better safety profile, improved quality of life and lower medical costs for patients. The promising results promote incorporating an outpatient postremission therapy model into clinical practice for both low-risk and high-risk APL patients in China. In this review, we discuss the evolution of oral arsenic RIF in the treatment of APL, with a special focus on how to address the related complications during induction therapy.
Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

Jing Fang,Sai-Juan Chen,Jian-Hua Tong,Zhu-Gang Wang,Guo-Qiang Chen,Zhu Chen

2002-01-01

Cancer Biology & Therapy

Abstract:Most acute promyelocytic leukemia (APL) cases have t(15;17)(q22;q21) chromosomal translocation and PML-RARalpha chimeric gene which blocks granulocytic differentiation. The introduction of all-trans-retinoic acid (ATRA) and arsenic compounds, especially arsenic trioxide (As(2)O(3)), has provided good models to study not only differentiation and/or apoptosis therapy but also molecular target-based cancer treatment. In vivo and in vitro investigations have shown that both agents are able to induce differentiation of APL cells: ATRA tends to induce terminal differentiation, while low-dose As(2)O(3) can induce partial differentiation. Significant progress has been made in understanding the molecular mechanisms of APL pathogenesis and differentiation therapy. Pharmacological concentrations (0.1 approximately 1 microM) of ATRA derepresses transcription by releasing CoR from, and recruiting CoA to PML-RARalpha, whereas As(2)O(3) triggers a rapid degradation of PML-RARalpha. In fact, the two drugs act on the same oncoprotein through targeting different moieties and in distinct ways and thereby abrogate its dominant-negative effects on regulatory pathways necessary for granulocytic differentiation. As to apoptosis, it is clear that high-dose As(2)O(3) can induce mitochondria-mediated cell death pathway in a thiol-dependent manner, while the mechanism of ATRA-induced apoptosis needs further elucidation. Transcriptomic and proteomic analysis are also expected to find new molecular targets. It is the hope that what we have learnt from APL will benefit further developments of anti-leukemia therapy.
A 3-Year Follow-Up of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (as2o3) As Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

J Hu,YF Liu,YM Zhu,ZZ Shi,JM Li,L Wang,Y Chen,ZX Shen

DOI: https://doi.org/10.1182/blood.v106.11.886.886

IF: 20.3

2005-01-01

Blood

Abstract:PURPOSE: To confirm the potential benefit of front-line use of all-trans retinoic acid (ATRA) combined with arsenic trioxide (As2O3) in patients with newly diagnosed acute promyelocytic leukemia (APL) with prolonged follow-up to median of 3-year and compared with historical control.
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia

Xian Zhang,Shulan Wu,Junfang Yang,Gailing Zhang,Yunchao Su,Min Zhang,Jiujiang He,Yanze Shi,Wenqian Li,Peihua Lu,Daopei Lu

DOI: https://doi.org/10.1007/s12185-022-03507-5

2022-01-01

International Journal of Hematology

Abstract:Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients received 3–5 cycles of chemotherapy followed by AS4S4 maintenance for 3 years. Eighty-eight ND APL patients were treated with either oral AS4S4 ( n = 42) or arsenic trioxide (ATO) ( n = 46). The 8-year overall survival (OS) rate was 100% in the AS4S4 group and 90% in the ATO group. The disease-free survival (DFS) rates were 100% and 87.1% ( p = 0.027), respectively. Patients in the ATO group had more side effects. A subsequent cohort of 33 ND APL patients received triple therapy with oral AS4S4, ATRA, and chemotherapy. The 13-year OS and DFS rates were 100% and 90.9%. Our long-term analyses show that APL patients with oral AS4S4 had better outcomes compared to ATO, with no need for hospitalization.
Arsenic in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Current Status and Future Research Direction

Jiong Hu

DOI: https://doi.org/10.1007/s11684-011-0117-y

2011-01-01

Frontiers of Medicine

Abstract:Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. In past decades, intensive studies on the biology and treatment of this disease have resulted in a remarkably thorough understanding of its pathogenesis and improvement of treatment outcomes. In particular, the introduction of all-trans retinoic acid to conventional chemotherapy improved dramatically the remission and survival rates of APL patients and consequently became the major treatment modality for it. In the last decade, the groundbreaking development of arsenic further improved the survival rate of APL patients. As the most active agent in APL, arsenic directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemia cells and the potential eradication of APL leukemiainitiating cells (LICs), thus making the disease a potentially curable type of leukemia. More notably, the recent development of oral arsenic compounds may further enhance not only clinical outcomes but also the convenience of patients, which may dramatically change the APL clinical scenario in the near future.
Combining Retinoic Acid and Oral Arsenic May Be Potentially the First-Line Therapy for Non-High-risk Acute Promyelocytic Leukemia.

Lin Fu,Jinlong Shi,Jia Liu,Anqi Liu,Kailin Xu,Xiaoyan Ke

DOI: https://doi.org/10.21037/sci.2016.11.13

2016-01-01

Stem Cell Investigation

Abstract:Once regarded as a rapidly fatal disease, acute promyelocytic leukemia (APL) is now curable in most cases with the use of targeted treatment alone and without chemotherapy (CHT) (1). Platzbecker et al . (2) reported a prospective, randomized, multicenter, open-label, phase III noninferiority trial, which demonstrated the advantages of all-trans-retinoic acid (ATRA) and intravenous ATO over ATRA and CHT with significantly greater and more sustainable antileukemic efficacy over time for non-high-risk APL. The recent paper by Iland et al . (3) also revealed that ATRA and arsenic in initial therapy induction and consolidation for APL reduced the risk of relapse compared with historical controls. These studies demonstrated the advantages of combining ATRA and intravenous ATO over ATRA and CHT for non-high-risk APL.
How All-Trans Retinoic Acid (ATRA) Was Discovered and Its Use in the Treatment of Acute Promyelocytic Leukaemia (APL)

Z. -Y. Wang,J. -Q. Mi,J. -M. Li

DOI: https://doi.org/10.1016/j.banm.2023.02.004

2023-01-01

Abstract:Following the Confucian thought that allows the transformation, the education of a bad element rather than its eradication, several authors, Israeli, Spanish and American have published encouraging results. We concluded negatively, using thioproline, after three years of testing, all this during the 1980s. Flynn, American researcher, used the cis form of retinoic acid with limited effects. In China, we were able to use all-transretinoic acid (ATRA) which was to prove much more effective in transforming promyelocytes into granulocytes either in the HL 60 cell line or in patient cells. It was in 1985 that, on compassionate grounds, we were able to cure a 5-year-old girl of her leukemia with ATRA. In 1987, and again in 1993, we were able to demonstrate the decisive action of ATRA, enhanced by the simultaneous use of arsenic trioxide (ATO), rather than chemotherapy. Promyelocytic leukemia, which was fatal within a few weeks before 1985, is more than 95% cured by 2023.(c) 2023 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All rights reserved.
All-Trans Retinoic Acid and Arsenic Combination Therapy Benefits Low-To-Intermediate-Risk Patients with Newly Diagnosed Acute Promyelocytic Leukaemia: A Long-Term Follow-Up Based on Multivariate Analysis

Hongming Zhu,Jiong Hu,Xiaoyang Li,Li Chen,Huijin Zhao,Wei Zhou,Lining Wang,Xia Zhao,Yunxiang Zhang,Yu Chen,Huiping Sun,Qiusheng Chen,Weili Zhao,Jianqing Mi,Zhixiang Shen,Zhu Chen,Zhenyi Wang,Junmin Li,Saijuan Chen

DOI: https://doi.org/10.1111/bjh.13375

2015-01-01

British Journal of Haematology

Abstract:All-trans retinoic acid (ATRA) and chemotherapy have enabled great improvements in the treatment of acute promyelocytic leukaemia (APL). High initial white blood cell (WBC) and low platelet counts are generally considered as independent risk factors for APL (Sanz et al, 2000). However, the relapse rate has been reported to be as high as 5–30% (Tallman, 2007). In 2001, a pilot clinical trial was held at Shanghai Institute of Haematology to treat APL with ATRA and arsenic combination therapy (Shen et al, 2004), and the 5-year follow-up (Hu et al, 2009) showed high efficacy. Since then, this approach has been shown not to be inferior to or even better than ATRA and chemotherapy. In the present study, we updated the follow-up to clarify the long-term survival and the risk factors in APL patients when using the ATRA and arsenic combination therapy. Between February 2001 and July 2010, 217 newly diagnosed APL patients were included in this study. Informed consent was obtained in all patients. The criteria for diagnosis, cytogenetic analysis and molecular tests for PML-RARA transcripts were performed as previously described (Shen et al, 2004), together with the treatment protocol (Table SI). Briefly, for induction therapy, all patients received ATRA and arsenic until documented complete remission (CR). Idarubicin (IDA) was given in case of high-risk patients. Three courses of consolidation therapy followed induction. The maintenance therapy consisted of 5 cycles of sequential use of ATRA, arsenic and low-dose chemotherapy (6-mercaptop-
Synergistic action of all-trans retinoic acid and arsenic in the treatment of acute promyelocytic leukaemialeukemia on transcriptional expression and epigenetic regulation

Y. Tan,Y. -W Cheng,K. -K Wang,S. -J Chen,J. -Q Mi,Z. Chen

2023-01-01

Abstract:Acute promyelocytic leukaemialeukemia (APL) has been transformed from a highly lethal type of leukaemia to a curable disease in more than 90% of cases, thanks to a treatment combining all-trans retinoic acid (ATRA) , arsenic. The two drugs target the retinoic acid receptor alpha receptor portion moiety and the PML moiety portion of the PML-RARa, the key oncoprotein in the pathogenesis of APL, respectively, resulting in multi-dimensional synergistic actions. It was shown that ATRA is able to restore the expression of PML-RARa-repressed genes and induce terminal differentiation of APL cells, while arsenic tends to exert an effect on protein networks deregulated by PML-RARa and triggers partial cell differentiation or programmed cell death, depending on the doses used. Then, we discovered, with Hugues de The's team, that the two drugs promote PML-RARa degradation through different mechanisms , the simultaneous effect between them allows a faster degradation of oncoprotein as well as an elimination of leukemic stem cells. Recently, we found a particular synergistic mechanism of ATRA and arsenic at the epigenetic level: more efficient regulation of PML-RARa target genes in hyper-acetylated chromatin regions.(c) 2023 Published by Elsevier Masson SAS on behalf of l'Academie nationale de medecine.
Clinical Observation on the Efficacy of All-Trans Retinoic Acid (atra) Combined with Arsenic Trioxide (as2o3) in Newly Diagnosed Acute Promyelocytic Leukemia (Apl).

YF Liu,ZX Shen,J Hu,YM Zhu,JM Li,JH You,Y Shen,ZZ Shi,SJ Chen,Z Chen,ZY Wang

DOI: https://doi.org/10.1182/blood.v104.11.888.888

IF: 20.3

2004-01-01

Blood

Abstract:OBJECTIVE To study whether all-trans retinoic acid (ATRA) combined with arsenic trioxide (As(2)O(3)) in acute promyelocytic leukemia (APL) treatment could further improve the clinical and molecular remission rate. METHOD Thirty one newly-diagnosed APL patients of whom 15 were males, 16 females and median age 35.4 years entered into the study. They were treated with ATRA 25 mg x m(-2) x d(-1) combined with As(2)O(3) 0.16 mg x kg(-1) x d(-1) until complete remission (CR). The doses were adjusted according to white blood cell (WBC) counts, occurrence of RA syndrome and the status of liver function. CR rate, time of reaching clinical and molecular remission and side effects were observed. RESULT Two patients died 2 approximately 3 days after the treatment due to intracranial hemorrhage, and 29 (93.5%) achieved CR. The average time for achieving CR was 25.1 +/- 3.9 days. Hyperleukocytosis emerged in 66.5% and hepatic damages in 65.5% of the patients, they were ameliorated within one week after reduction of the As(2)O(3) dose or its suspension. The PML/RAR alpha fusion gene that was positive in all 29 patients before treatment turned negative only in 3 cases (10.3%) after obtaining CR (CR1) and in 10/13 cases (77%) after consolidation treatment. Up to now (1-8 months follow-up), all 29 patients remain in CR1. CONCLUSION ATRA combined with As(2)O(3) in de novo APL treatment can yield a high CR rate without intolerable side effects. Long term effect needs further observation.
Long-Term Follow-Up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Hongming Zhu,Jiong Hu,Li Chen,Wei Zhou,Xiaoyang Li,Wang Lining,Xia Zhao,Yunxiang Zhang,Huijin Zhao,Yu Chen,Huiping Sun,Qiusheng Chen,Weili Zhao,Jianqing Mi,Zhixiang Shen,Saijuan Chen,Zhenyi Wang,Junmin Li

DOI: https://doi.org/10.1182/blood.v124.21.282.282

IF: 20.3

2014-01-01

Blood

Abstract:Objective: All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) combination therapy for newly diagnosed acute promyelocytic leukemia (APL) has yielded high efficacy in clinical trials, but there are few studies focusing on the long-term follow-up of survival and complications.

Retinoic acid and arsenic for treating acute promyelocytic leukemia.

Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

The Simpler, The Better: Oral Arsenic For Acute Promyelocytic Leukemia

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.

Oral Arsenic And All-Trans Retinoic Acid For High-Risk Acute Promyelocytic Leukemia

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

Long-Term Efficacy and Safety of All-Trans Retinoic Acid/Arsenic Trioxide-Based Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia.

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

A 3-Year Follow-Up of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (as2o3) As Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia

Arsenic in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Current Status and Future Research Direction

Combining Retinoic Acid and Oral Arsenic May Be Potentially the First-Line Therapy for Non-High-risk Acute Promyelocytic Leukemia.

How All-Trans Retinoic Acid (ATRA) Was Discovered and Its Use in the Treatment of Acute Promyelocytic Leukaemia (APL)

All-Trans Retinoic Acid and Arsenic Combination Therapy Benefits Low-To-Intermediate-Risk Patients with Newly Diagnosed Acute Promyelocytic Leukaemia: A Long-Term Follow-Up Based on Multivariate Analysis

Synergistic action of all-trans retinoic acid and arsenic in the treatment of acute promyelocytic leukaemialeukemia on transcriptional expression and epigenetic regulation

Clinical Observation on the Efficacy of All-Trans Retinoic Acid (atra) Combined with Arsenic Trioxide (as2o3) in Newly Diagnosed Acute Promyelocytic Leukemia (Apl).

Long-Term Follow-Up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy